Last reviewed · How we verify
SB751689
At a glance
| Generic name | SB751689 |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of SB751689 in Japanese Postmenopausal Women (PHASE1)
- A Phase II Study Evaluating SB-751689 in Post-Menopausal Women With Osteoporosis. (PHASE2)
- An Adaptive Phase I Study to Evaluate the Safety, Efficacy and Dose Responses of Ronacaleret in Healthy Human Volunteers (PHASE1)
- Study in Healthy Volunteers, to Evaluate the Safety, Efficacy and Dose Responses of SB-751689 (Ronacaleret) (PHASE1)
- A Phase IIa Study Of Men And Post-Menopausal Women With A Fractured Distal Radius (PHASE2)
- A Study to Evaluate the Effects of SB-751689 or rhPTH(1-34) on Excretion of Calcium and Phosphate in Women (PHASE1)
- A Study To Evaluate The Effects Of Repeat Dosing Of Esomeprazole On The Pharmacokinetics Of SB-751689 In Healthy People (PHASE1)
- A Study to Estimate the Effect of Formulation on the Relative Absorption of SB-751689 Administered to Healthy Women (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SB751689 CI brief — competitive landscape report
- SB751689 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI